SANOFI-AVENTIS (EPA:SAN) ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)
Directive transparence : information réglementée
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show...
Press Release: Sanofi cuts U.S. list price of Lantus®, its...
Information concerning the total number of voting rights and shares –...
Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of...
ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers...
Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of...
Press Release: Sanofi announces change in R&D leadership
Press Release : Strong sales performance and double digit EPS growth...
Sanofi: Information concerning the total number of voting rights and...
Sanofi: Disclosure of trading in own shares
Voir tous les communiqués de SANOFI-AVENTIS
©Dissemination technology Webdisclosure.com - copyright 2023 SYMEX ECONOMICS all rights reserved